The overview of Clarithromycin treatment for Helicobacter pylori infection

Yang Chen

doi:10.54254/2753-8818/46/20240604

Research Article

Open access

Published on 31 July 2024

Download pdf

Chen,Y. (2024). The overview of Clarithromycin treatment for Helicobacter pylori infection. Theoretical and Natural Science,46,142-148.

Export citation

The overview of Clarithromycin treatment for Helicobacter pylori infection

Yang Chen *^,1,

¹ University of Iowa

* Author to whom correspondence should be addressed.

https://doi.org/10.54254/2753-8818/46/20240604

Abstract

Helicobacter pylori (H. pylori) is a Gram-negative bacillus that causes infections worldwide. Helicobacter pylori's drug resistance and infectivity are vital factors causing Helicobacter pylori infection. The virulence factors of Helicobacter pylori include acid escape virulence factors and epithelial cell colonizing factors, which can directly or indirectly cause chronic gastritis or gastric ulcer. As the resistance of Helicobacter pylori increases, a combination of multiple antibiotics is now the recommended therapy, and clarithromycin is one of them. The production process of clarithromycin and its effectiveness are essential points of discussion.

Keywords

Bacterial infection, Helicobacter pylori, Virulence factors, Clarithromycin

View pdf

References

[1]. FitzGerald R, Smith SM. An Overview of Helicobacter pylori Infection. Methods Mol Biol. 2021;2283:1-14. doi: 10.1007/978-1-0716-1302-3_1. PMID: 33765303.

[2]. de Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, Neves PHM, de Melo FF. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol. 2019 Oct 7;25(37):5578-5589. doi: 10.3748/wjg.v25.i37.5578. PMID: 31602159; PMCID: PMC6785516.

[3]. Šterbenc A, Jarc E, Poljak M, Homan M. Helicobacter pylori virulence genes. World J Gastroenterol. 2019 Sep 7;25(33):4870-4884. doi: 10.3748/wjg.v25.i33.4870. PMID: 31543679; PMCID: PMC6737321.

[4]. Leung WK, Graham DY. Clarithromycin for Helicobacter pylori infection. Expert Opin Pharmacother. 2000 Mar;1(3):507-14. doi: 10.1517/14656566.1.3.507. PMID: 11249534.

[5]. Ansari S, Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019 Nov 19;11(11):677. doi: 10.3390/toxins11110677. PMID: 31752394; PMCID: PMC6891454.

[6]. Clarithromycin. New Drug Approvals. (2021, April 4). https://newdrugapprovals.org/2021/04/01/clarithromycin/

[7]. Leung WK, Graham DY. Clarithromycin for Helicobacter pylori infection. Expert Opin Pharmacother. 2000 Mar;1(3):507-14. doi: 10.1517/14656566.1.3.507. PMID: 11249534.

[8]. Marques AT, Vítor JMB, Santos A, Oleastro M, Vale FF. Trends in Helicobacter pylori resistance to clarithromycin: from phenotypic to genomic approaches. Microb Genom. 2020 Mar;6(3):e000344. doi: 10.1099/mgen.0.000344. PMID: 32118532; PMCID: PMC7200067.

Cite this article

Chen,Y. (2024). The overview of Clarithromycin treatment for Helicobacter pylori infection. Theoretical and Natural Science,46,142-148.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 2nd International Conference on Modern Medicine and Global Health

Conference website: https://www.icmmgh.org/

ISBN：978-1-83558-569-6(Print) / 978-1-83558-570-2(Online)

Conference date: 5 January 2024

Editor：Mohammed JK Bashir

Series: Theoretical and Natural Science

Volume number: Vol.46

ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).